Haemonetics Corp/Mass
HAEAbove valueExpectations · demandingHeld by 2 superinvestors.
SEC 10-K · fundamentals
Business quality
as of 2026-03-28Valuation basis: trailing twelve months to 2026-06-27 — latest 10-K plus unaudited 10-Q filings.
- Revenue growth
- -2.0%
- Net margin
- 7.3%
- ROE
- 12.2%
- FCF margin
- 19.5%
Valuation · value band
Above fair value
Zero-growth floor
$19
Central IV
$41
Optimistic top
$62
Haemonetics Corp/Mass (HAE): Two methods value the business — a conservative owner-earnings DCF and a growth-credited Greenwald estimate, $19–$62 / sh. Today’s price sits above both (price $108 as of 2026-08-25).
The middle figure is the main read. The right end is the optimistic case under the same conservative caps — not an absolute ceiling.
Revenue growth 4% (lower of historical trend and fundamental cap, capped by moat) · moat 10 yr · discount 12.1% · Zero-growth downside $19
Price as of 2026-08-25 · yahoo · DGS10 4.7% @ 2026-08-24.
Method & numbers
A conservative intrinsic-value band (zero-growth floor to growth-capped DCF) plus a tangible asset floor — not investment advice, not a buy/sell signal, and not a price target.
Owner-earnings DCF $28.91 – $48.10 · Greenwald $39.37 – $61.63 (neutral $49.48) · zero-growth base $33.44 · reproduction $9.20
Moat Franchise (moat) · terminal value 42% of present value · owner-earnings yield 3% vs 10Y 4.7%.
Graham earnings-power value (normalized NOPAT)$18.52 – $27.26 / sh
Normalized NOPAT = average operating margin over the years shown × latest-year revenue × (1 − normalized tax); then + D&A − maintenance capex (write A). Unlevered (pre-interest, attributable to all capital). Capitalized at the 9–11% rate band (read as a WACC proxy). Enterprise → equity bridge applied: + cash − total debt.
Years: TTM 2026-06-27, 2024, 2023, 2022, 2021
v1 simplifications: Maintenance capex (degraded) deducted in full cash (write A): EPV = (NOPAT + D&A − maintenance capex) / WACC; no tax shield on the capex term. Maintenance-capex methods diverge by 204% (> 50%); estimate is degraded. Share-based compensation is left as a real expense (not added back). Operating margin is below its multi-year average (cyclical/declining): normalized margin capped at the latest year — no peak-margin capitalization (audit #2).
Buffett owner-earnings value$28.08 – $33.44 / sh
Owner earnings = average net income + average D&A − maintenance capex (zero-growth floor; no ΔNWC). Levered (starts from net income, already after interest — an equity-holder stream). Capitalized at the 10.5–12.5% band (9–11% base + 1.5pp leverage premium). No enterprise→equity bridge: the capitalized result is already equity value (subtracting debt would double-count interest).
Years: TTM 2026-06-27, 2024, 2023, 2022, 2021
v1 simplifications: Net income is below its multi-year average (cyclical/declining): normalized owner earnings anchored to the latest year — no peak-earnings capitalization (audit #2). Owner earnings = net income + D&A − maintenance capex (degraded); the working-capital change is excluded (maintenance ΔNWC ≈ 0; growth ΔNWC is carried in growth value, not double-counted). Maintenance-capex methods diverge by 204% (> 50%); estimate is degraded. One-time items are not separately normalized (multi-year averaging smooths them partially). Share-based compensation is left as a real expense (not added back); see the SBC/OE disclosure. Capitalized at the 9–11% base band plus a 1.5pp leverage premium (cost of equity rises with leverage — MM Proposition II). Net debt is about 5.9 years of owner earnings, adding 1.5pp of cost-of-equity risk premium.
Reproduction value = tangible net assets $-254.29M + capitalized R&D $129.14M（FY 2026, 2024, 2023, 2022） = $9.20 / sh. Reproduction value = intangible-inclusive net reproduction (tangible net assets + acquired-intangible reset proxy + capitalized R&D), ÷ diluted shares; tangible net assets alone are negative for this asset-light franchise.
Moat reading: Franchise test compares earnings power (EPV) against reproduction value (tangible net assets + capitalized R&D). EPV well above reproduction value signals a moat; near it, a commodity; below it, value destruction. A directional reading, not a verdict.
Assumes a narrow moat · competitive-advantage period ≈ 10 years.
Growth value: if the moat holds for 10 yr at ROIIC ≈ 23%, $5.92–$28.19 / sh (neutral $16.03). Conservative, not a forecast.
Window TTM 2026-06-27, FY 2024, 2023, 2022, 2021 · discount band 9%–11% · normalized tax 21% (Average effective tax rate over 5 year(s), capped at the statutory 21%.) · diluted shares.
Baseline 9%–11%, net debt ≈ 5.9 years of owner earnings → +1.5pp cost-of-equity premium → effective 10.5%–12.5%.
Owner-earnings DCF: growth g₁ 4% · OE FY TTM 2026-06-27, 2024, 2023, 2022, 2021 · Discount band: 10.67%–13.47% (DGS10 +4.5% to a 12% strict end, each +1.47pp for leverage premium, as of 2026-08-24). No enterprise→equity bridge: owner earnings already flow to shareholders (post-interest), so no net cash is added and no debt subtracted — matching the engine owner-earnings lamp. Two-method midpoint gap 19%.
Valuation basis: trailing twelve months to 2026-06-27 — latest 10-K plus unaudited 10-Q filings.
What the price is betting
Today's price pencils in about 23.3% a year in owner-earnings for the next few years. Revenue actually grew 9.6% a year.
The market wants it well ahead of its own track record.
SEC 13F · holders
Superinvestors Holding This Security
2 holders · $159.1M combined · this quarter +1 opened / -0 exited
- Value$154.6MWeight (prev→now)New · 1.5%
- Value$4.5MWeight (prev→now)0.0% → 0.0% ▲
SEC 13F · notes
Written summary
Written summary
Haemonetics Corp/Mass (HAE) is held by 2 of the superinvestors tracked on Compounder, with a combined $159.1M in reported 13F value. The largest position belongs to John Rogers, where it makes up 1.5% of the portfolio.
Other notable holders by value include Ray Dalio (0.0% of its book).
Over the latest quarter, 1 of the tracked filers opened a new position in HAE, 1 added to existing ones, 0 trimmed, and 0 sold out entirely.
Holder counts and values reflect the most recent SEC Form 13F filings, through the quarter ended 2026-06-30. Source: SEC EDGAR. A 13F shows only long US-listed positions and can lag the real portfolio by up to 45 days, so this is disclosed long ownership, not a complete picture.
SEC 13F · co-ownership
Also held by these investors
Investors holding Haemonetics Corp/Mass (HAE) also commonly hold →
- Jones Lang Lasalle IncJLL2 holders
- Generac Holdings IncGNRC2 holders
- Middleby CorpMIDD2 holders
- Zebra Technologies Corp-Cl AZBRA2 holders
- Envista Holdings CorpNVST2 holders
- Prestige Consumer HealthcarePBH2 holders
HAE's price is not below its conservative value band. See current strike-zone stocks
Sources· SEC EDGAR 13F as of 2026-06-30 · filed 2026-08-14
Educational data only — not investment advice. 13F positions are self-reported and can lag up to 45 days.
Stay Updated
New-quarter 13F moves and valuation updates, to your inbox.